InMed Pharmaceuticals reports beneficial ownership disclosure by ADAR1 Capital Management and Daniel Schneeberger. The filing states 800,000 shares of Common Shares are beneficially owned by private funds managed by ADAR1 Capital Management, representing 24.1% of Common Shares based on May 4, 2026 outstanding shares of 3,314,063. The filing notes these shares are held directly by ADAR1-managed funds and may be indirectly beneficially owned by Daniel Schneeberger as sole manager.
Positive
None.
Negative
None.
Insights
Large passive disclosure: a 24.1% reported stake by an adviser-managed fund and its manager.
The filing lists 800,000 shares held by private funds managed by ADAR1 Capital Management, LLC, which equals 24.1% of the company's 3,314,063 outstanding shares as of May 4, 2026. The report attributes indirect beneficial ownership to Daniel Schneeberger as the funds' sole manager.
Implications hinge on whether holdings are passive or active; the schedule is a disclosure of ownership rather than an intent to acquire or dispose. Subsequent disclosures or amendments would clarify changes; cash‑flow treatment and trading intentions are not included in the excerpt.
Key Figures
Shares beneficially owned:800,000 sharesPercent of class:24.1%Shares outstanding:3,314,063 shares
3 metrics
Shares beneficially owned800,000 sharesReported beneficial ownership by ADAR1-managed funds
Percent of class24.1%Based on outstanding shares as of <date>May 4, 2026</date>
Shares outstanding3,314,063 sharesOutstanding Common Shares as of <date>May 4, 2026</date>
Key Terms
Schedule 13G, beneficially owned, shared dispositive power
3 terms
Schedule 13Gregulatory
"This Schedule is being filed on behalf of each of the following persons"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"Shared Dispositive Power 800,000.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did ADAR1 report in INM?
ADAR1 reported beneficial ownership of 800,000 shares of INM common stock. The filing shows this equals 24.1% of 3,314,063 shares outstanding as of May 4, 2026, and the shares are held by private funds managed by ADAR1.
Does Daniel Schneeberger directly own the shares in INM?
Mr. Schneeberger is reported as the sole manager of ADAR1 and may indirectly beneficially own the shares. The filing states the 800,000 shares are held by ADAR1-managed funds and that Mr. Schneeberger may be deemed an indirect beneficial owner.
How was the 24.1% ownership percentage calculated?
The percentage is based on 3,314,063 Common Shares outstanding as of May 4, 2026. The filer explicitly ties the 24.1% figure to that outstanding share count from the company's Form 10-Q for the quarter ended March 31, 2026.
Does the Schedule 13G indicate trading intentions by ADAR1 or Schneeberger?
No—this Schedule 13G provides beneficial ownership disclosure and does not state trading intentions. The filing lists holdings and voting/dispositive power but does not describe any planned purchases or sales.
Where is ADAR1 located and under what authority did it file?
ADAR1 Capital Management is a Texas limited liability company with principal business at 3503 Wild Cherry Drive, Austin, Texas. Mr. Schneeberger filed as a control person in respect of shares beneficially owned by ADAR1, per the filing language.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
InMed Pharmaceuticals, Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
457637700
(CUSIP Number)
05/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
457637700
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
800,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
800,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
800,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
24.1 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 800,000 shares of common shares, no par value ("Common Shares"), of InMed Pharmaceuticals, Inc. (the "Company") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 3,314,063 shares of Common Shares outstanding as of May 4, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
457637700
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
800,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
800,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
800,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
24.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 800,000 shares of common shares, no par value ("Common Shares"), of InMed Pharmaceuticals, Inc. (the "Company") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 3,314,063 shares of Common Shares outstanding as of May 4, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
InMed Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
Suite 1445 - 885 W. Georgia Street Vancouver, A1 V6C 3E8
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and
(ii) Daniel Schneeberger ("Mr. Schneeberger").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company; and
(ii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP Number(s):
457637700
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
